Skip to main
PRME

PRME Stock Forecast & Price Target

PRME Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 25%
Buy 50%
Hold 25%
Sell 0%
Strong Sell 0%

Bulls say

Prime Medicine is a promising biotechnology company with a potential best-in-class AATD program that targets a significant unmet need. Its versatile prime editing platform, validated by early clinical data and a partnership with BMS, adds value to its other pipeline programs, including its potentially best-in-class AATD program. With major upcoming catalysts and a strong management team, Prime Medicine is poised for success.

Bears say

Prime Medicine is a relatively new company with a promising but unproven gene-editing technology for the treatment of genetic diseases, such as Wilson Disease and AATD. However, with limited financial resources and no approved therapies, the company faces significant financial and commercialization risks. Furthermore, competition from other genetic medicines and potential high pricing of its therapies may limit the company's market potential, leading to a negative outlook for its stock.

PRME has been analyzed by 4 analysts, with a consensus rating of Buy. 25% of analysts recommend a Strong Buy, 50% recommend Buy, 25% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Prime Medicine Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Prime Medicine Inc (PRME) Forecast

Analysts have given PRME a Buy based on their latest research and market trends.

According to 4 analysts, PRME has a Buy consensus rating as of Jun 3, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.56, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.56, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Prime Medicine Inc (PRME)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.